Moxifloxacin Kabi (Moxifloxacin Hydrochloride)

Moxifloxacin, the active ingredient in Moxifloxacin Kabi, is a fluoroquinolone antibiotic presented as an intravenous solution for intravenous use. It treats a range of serious bacterial infections in adult patients, including community‑acquired pneumonia, acute bacterial sinusitis, acute exacerbations of chronic bronchitis, complicated skin and skin‑structure infections, and complicated intra‑abdominal infections.

GNH USA supplies Moxifloxacin Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Moxifloxacin is a fluoroquinolone antibiotic used to treat bacterial infections of the respiratory, skin and intra‑abdominal systems. - Community‑acquired pneumonia: achieves clinical cure and bacterial eradication in adult patients. - Acute bacterial sinusitis: reduces symptoms and eliminates causative pathogens. - Acute exacerbations of chronic bronchitis: improves lung function and shortens disease duration. - Complicated skin and skin structure infections: facilitates resolution of infection and promotes healing. - Complicated intra‑abdominal infections: supports clearance of intra‑abdominal pathogens and recovery.

Moxifloxacin may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: loose stools, often self‑limiting. - Headache: transient cranial discomfort. - Rash: mild skin erythema or pruritus.

Serious or Rare Side Effects: - Tendon rupture: sudden tendon pain or rupture, especially in the Achilles. - QT interval prolongation: risk of cardiac arrhythmia, monitor ECG. - Severe hypersensitivity reactions: anaphylaxis or Stevens‑Johnson syndrome. - Clostridioides difficile‑associated colitis: severe diarrhea due to gut flora disruption.

Use of Moxifloxacin requires careful assessment of patient-specific factors and monitoring for potential complications. - Renal impairment: adjust therapy and monitor renal function. - Hepatic dysfunction: use with caution; monitor liver enzymes. - History of tendon disorders: avoid use due to risk of tendon rupture. - Cardiac arrhythmias: assess QT interval before therapy. - Concomitant QT‑prolonging drugs: avoid combination to reduce arrhythmia risk. - Store at 2‑8°C: keep refrigerated, protect from light, do not freeze.

Moxifloxacin can interact with several medicines, necessitating clinical vigilance.

Major Interactions (Avoid): - Antacids containing aluminum or magnesium: reduce absorption, avoid concurrent use. - Warfarin: may increase INR, monitor coagulation. - Theophylline: increased plasma levels, monitor for toxicity.

Moderate Interactions (Monitor Closely): - NSAIDs: may increase risk of central nervous system effects. - Corticosteroids: heightened risk of tendon rupture. - Oral contraceptives: possible reduction in efficacy, advise alternative contraception.